PMID- 32201153
OWN - NLM
STAT- MEDLINE
DCOM- 20210326
LR  - 20210326
IS  - 2589-0646 (Electronic)
IS  - 2589-0646 (Linking)
VI  - 13
IP  - 4
DP  - 2020 Dec
TI  - Alternative donor hematopoietic stem cell transplantation for sickle cell disease 
      in Europe.
PG  - 181-188
LID - S1658-3876(20)30034-0 [pii]
LID - 10.1016/j.hemonc.2019.12.011 [doi]
AB  - Allogeneic hematopoietic stem cell transplantation (HSCT) is, to date, the only 
      curative treatment for sickle cell disease (SCD). Because an human leukocyte 
      antigen (HLA)-matched sibling donor is not always available, alternative stem 
      cell sources such as unrelated or haploidentical related donors have been 
      explored. To date, few series of SCD patients transplanted with an unrelated 
      donor, cord blood, and haploidentical related donor have been reported, but the 
      high rates of rejection and chronic graft versus host disease have limited their 
      widespread application. We describe the outcomes of a retrospective, 
      registry-based, survey on 144 alternative donor HSCT performed for SCD in 30 
      European Society for Blood and Marrow Transplantation centers between 1999 and 
      2017. Data on 70 unrelated adult donors (49%), six cord blood (4%), and 68 
      haploidentical donors (47%; including post-HSCT Cy, ex vivo T-cell depleted, and 
      other haplo-HSCTs) were reported and missing information was updated by the 
      centers. Overall, 16% patients experienced graft failure, Grade II-IV acute GVHD 
      at 100 days was 24%, whereas Grade III-IV was 10%. Chronic GVHD was observed in 
      24% (limited for 13 patients and extensive for 18 patients). Overall, the 3-year 
      overall survival (OS) was 86% +/- 3% and 3-year event-free survival (EFS; 
      considering death and graft failure as events) was 72% +/- 4%. We therefore 
      conclude that alternative donor HSCT for SCD can be feasible but efforts in 
      decreasing relapse and GVHD should be promoted to increase its safe and 
      successful utilization. Moreover, a better knowledge of HLA matching and the 
      tailoring of conditioning could help improve EFS and OS.
CI  - Copyright (c) 2020 King Faisal Specialist Hospital & Research Centre. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Gluckman, Eliane
AU  - Gluckman E
AD  - Monacord, Centre Scientifique de Monaco, Monaco; Eurocord, Hopital Saint Louis, 
      Universite Paris Diderot, Paris, France. Electronic address: 
      eliane.gluckman@aphp.fr.
FAU - Cappelli, Barbara
AU  - Cappelli B
AD  - Monacord, Centre Scientifique de Monaco, Monaco; Eurocord, Hopital Saint Louis, 
      Universite Paris Diderot, Paris, France.
FAU - Scigliuolo, Graziana Maria
AU  - Scigliuolo GM
AD  - Monacord, Centre Scientifique de Monaco, Monaco; Eurocord, Hopital Saint Louis, 
      Universite Paris Diderot, Paris, France.
FAU - De la Fuente, Josu
AU  - De la Fuente J
AD  - Department of Pediatrics, St Mary's Hospital, Imperial College, London, UK.
FAU - Corbacioglu, Selim
AU  - Corbacioglu S
AD  - Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, 
      University of Regensburg, Regensburg, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200316
PL  - Saudi Arabia
TA  - Hematol Oncol Stem Cell Ther
JT  - Hematology/oncology and stem cell therapy
JID - 101468532
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anemia, Sickle Cell/*mortality/*therapy
MH  - Child
MH  - Child, Preschool
MH  - Disease-Free Survival
MH  - Europe/epidemiology
MH  - Female
MH  - Graft vs Host Disease/etiology/*mortality/prevention & control
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Lymphocyte Depletion
MH  - Male
MH  - Middle Aged
MH  - Survival Rate
MH  - *Transplantation Conditioning
MH  - *Unrelated Donors
OTO - NOTNLM
OT  - Alternative donor HSCT
OT  - Haploidentical HSCT
OT  - Sickle cell disease
OT  - Unrelated donor HSCT
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/03/24 06:00
MHDA- 2021/03/27 06:00
CRDT- 2020/03/24 06:00
PHST- 2019/10/31 00:00 [received]
PHST- 2019/12/11 00:00 [accepted]
PHST- 2020/03/24 06:00 [pubmed]
PHST- 2021/03/27 06:00 [medline]
PHST- 2020/03/24 06:00 [entrez]
AID - S1658-3876(20)30034-0 [pii]
AID - 10.1016/j.hemonc.2019.12.011 [doi]
PST - ppublish
SO  - Hematol Oncol Stem Cell Ther. 2020 Dec;13(4):181-188. doi: 
      10.1016/j.hemonc.2019.12.011. Epub 2020 Mar 16.